To evaluate the expression of PARP1 in chordoma and analyzed its association with clinical factors and patients' prognosis.
METHODS:
The expression of Poly (ADP-ribose) polymerase 1 (PARP1) in chordoma specimens from 74 chordoma patients (50 primary and 24 recurrent tumors of 50 patients)and 20 distant normal tissue specimens was measured by immunohistochemical staining. The association of PARP1with the clinical factors and patients' prognosis was also analyzed.
RESULTS:
Of all the chordoma samples, 78% showed high expression of PARP1, whereas, only 10% of distant normal tissues expressed a high level of PARP1 (p< 0.01). Chi-square analysis revealed that high expression of PARP1 was significantly correlated with tumor recurrence (p< 0.01) and invasion into surrounding muscle (p< 0.01), while the data did not indicate any association with patients' gender, age, tumor location and size(p> 0.05). Kaplan-Meier survival curve and log-rank test showed that continuous disease free survival time (CDFS) was significantly shorter in the PARP1-positive group than in the PARP1-negative group (P= 0.019).
CONCLUSION:
High expression of PARP1 is significantly associated with chordoma invasion and recurrence. PARP1 may become a potential biomarker for chordoma in predicting its recurrence and patients' prognosis.
MatsumotoT., ImagamaS., ItoZ., ImaiR., KamadaT., ShimoyamaY., MatsuyamaY. and IshiguroN., Total spondylectomy following carbon ion radiotherapy to treat chordoma of the mobile spine, Bone Joint J95-B(10) (2013), 1392-1395.
2.
MacMasterM.S., GoldsteinA.M., BromleyC.M., IshibeN. and ParryD.M., Chordoma: incidence and survival patterns in the United States, 1973-1995, Cancer Causes Control12(1) (2001), 1-11.
3.
BerghP., KingblomL.G.GunterbergB., RemottiF., RydW. and Meis-KindblomJ.M., Prognostic factors in chordoma of the sacrum and mobile spine. A study of 39 patients, Cancer88(9) (2000), 2122-2134.
4.
MoojenW.A., Vleggeert-LankampC.L., KrolA.D. and DijkstraS.P., Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable, Spine (Phila Pa 1976)36(10) (2011), E656-61.
5.
McPhersonC.M., SukiD., McCutcheonI.E., GokaslanZ.L., RhinesL.D. and MendelE., Metastatic disease from spinal chordoma: a 10-year experience, J Neurosurg Spine5(4) (2006), 277-280.
6.
RuggieriP., AngeliniA., UssiaG., MontaltiM. and MercuriM., Surgical margins and local control in resection of sacral chordomas, Clin Orthop Relat Res468(11) (2010), 2939-2947.
7.
SciubbaD.M., ChengJ.J., PetteysR.J., WeberK.L., FrassicaD.A. and GokaslanZ.L., Chordoma of the sacrum and vertebral bodies, J Am Acad Orthop Surg17(11) (2009), 708-717.
8.
HannaS.A., AstonW.J., BriggsT.W., CannonS.R. and SaifuddinA., Sacral chordoma: can local recurrence after sacrectomy be predicted?Clin Orthop Relat Res466(9) (2008), 2217-2223.
9.
ZarembaT. and CurtinN.J., PARP inhibitor development for systemic cancer targeting, Anticancer Agents Med Chem7(5) (2007), 515-523.
10.
RouleauM., PatelA., HendzelM.J., KaufmannS.H. and PoirierG.G., PARP inhibition: PARP1 and beyond, Nat Rev Cancer10(4) (2010), 293-301.
11.
DeshmukhD. and QiuY., Role of PARP-1 in prostate cancer, Am J Clin Exp Urol3(1) (2015), 1-12.
12.
ScheiplS., LohbergerB., RinnerB., FroehlichE.V., BehamA., QuehenbergerF., LazáryA., Pal VargaP., HaybaeckJ., LeithnerA. and LieglB., Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: an immunohistochemical and functional analysis, J Orthop Res31(12) (2013), 1999-2005.
13.
YangH., ZhuL., EbraheimN.A., LiuX., CastilloS., TangT., LiuJ. and CuiH., Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization, Spine J9(12) (2009), 972-980.
14.
ChenK., MoJ., ZhouM., WangG., WuG., ChenH., ZhangK. and YangH., Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis, Med Oncol31(4) (2014), 886.
15.
ChenK.W., YangH.L., LuJ., LiuJ.Y. and ChenX.Q., Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients, Spinal Cord48(2) (2010), 166-171.
16.
ChenK.W., YangH.L., LuJ., WangG.L., JiY.M., WuG.Z., ZhuL.F., LiuJ.Y., ChenX.Q. and GuY.P., Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma, J Neurooncol101(3) (2011), 357-363.
17.
RinnerB., FroehlichE.V., BuergerK., KnauszH., LohbergerB., ScheiplS., FischerC., LeithnerA., GuellyC., TrajanoskiS., SzuhaiK. and LieglB., Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1, Int J Oncol40(2) (2012), 443-451.
18.
NaZ., PengB., NgS., PanS., LeeJ.S., ShenH.M. and YaoS.Q., A small-molecule protein-protein interaction inhibitor of PARP1 that targets its BRCT domain, Angew Chem Int Ed Engl54(8) (2015), 2515-2519.
19.
XuZ., ZhangL., ZhangW., MengD., ZhangH., JianY., XuX., Van MeterM., SeluanovA., GorbunovaV. and MaoZ., SIRT6 rescues the age related decline in base excision repair in a PARP1-dependent manner, Cell Cycle14(2) (2015), 269-276.
20.
BaoM., ChenZ., XuY., ZhaoY., ZhaR., HuangS., LiuL., ChenT., LiJ., TuH. and HeX., Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma, Liver Int32(2) (2012), 331-338.
21.
VeithS. and MangerichA., RecQ helicases and PARP1 team up in maintaining genome integrity, Ageing Res Rev23(Pt A) (2015), 12-28.
22.
ScheilS., BruderleinS., LiehrT., StarkeH., HermsJ., SchulteM. and MöllerP., Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1, Genes Chromosomes Cancer32(3) (2001), 203-211.
23.
Akhavan-SigariR., GaabM.R., RohdeV., AbiliM. and OstertagH., Expression of PDGFR-alpha, EGFR and c-MET in spinal chordoma: a series of 52 patients, Anticancer Res34(2) (2014), 623-630.
24.
SajishM. and SchimmelP., A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol, Nature519(7543) (2015), 370-373.
25.
GreenA.R., CaracappaD., BenhasounaA.A., AlshareedaA., NolanC.C., MacmillanR.D., MadhusudanS., EllisI.O. and RakhaE.A., Biological and clinical significance of PARP1 protein expression in breast cancer, Breast Cancer Res Treat149(2) (2015), 353-362.
26.
SabbatinoF., FuscielloC., SommaD., PacelliR., PoudelR., PepinD., LeonardiA., CarlomagnoC., Della Vittoria ScarpatiG., FerroneS. and PepeS., Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation, Cytometry A85(11) (2014), 953-961.
27.
DziamanT., LudwiczakH., CieslaJ.M., BanaszkiewiczZ., WinczuraA., ChmielarczykM., WisniewskaE., MarszalekA., TudekB. and OlinskiR., PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1, PLoS One9(12) (2014), e115558.
